InvestorsHub Logo
Followers 5
Posts 654
Boards Moderated 1
Alias Born 10/11/2014

Re: None

Friday, 11/03/2017 1:12:20 PM

Friday, November 03, 2017 1:12:20 PM

Post# of 1448

I fully expect results from the first of the 10 patients to be enrolled in the study will be starting to roll in. What will happen, if the news is good to spectacular, might well be very positive for share holders.

In the meantime we all can look forward to news regarding enrollment and iblue on the first patient.

Think about that guy/gal, if this works as advertised, see's the margins very clearly, the surgeon sees more cancer and gets all the cancer. Maybe they stop their cancer from coming back?

We'll be finding out soon enough. If it works as advertised, and remember all IME is doing is refining upgrading the technology from Lawrence Livermore. At Livermore US$4.5-5M was spent over 4 years, and numerous prototypes were built in the process of getting it right.

The way I see it IME's job is to prove, commercialize and sell what is, imo, essentially already a proven technology - it was used on 21 patients at Livermore/Davis and has been 'bench' tested at UofR.

Time will, as always provide clarity